Publications by authors named "E Revuelta-Lopez"
Soluble ST2 (sST2) is released in response to vascular congestion, inflammation, and pro-fibrotic stimuli. In heart failure (HF), elevated levels of sST2 are associated with a higher risk of adverse clinical outcomes. Emerging evidence suggests that carbohydrate antigen 125 (CA125) may act as a ligand that modulates the inflammatory response.
View Article and Find Full Text PDFArticle Synopsis
- The PERISCOPE Phase I clinical trial assessed the safety of PeriCord, a tissue graft made from decellularised pericardial matrix and umbilical cord mesenchymal cells, in patients undergoing surgical revascularization after non-acute myocardial infarction.
- In the trial, seven patients received PeriCord and demonstrated no adverse effects during the one-year follow-up, although there were no significant changes in overall quality of life or cardiac function compared to controls.
- The study highlighted PeriCord's immunomodulatory effects, specifically in influencing the behavior of circulating monocytes towards a repair-promoting state, indicating potential for further exploration in treating inflammation-related conditions.
Article Synopsis
- The study investigated whether the PCSK9 inhibitor evolocumab could reduce troponin levels in patients with stable heart failure with reduced ejection fraction (HFrEF) of ischaemic origin, suggesting a potential to limit disease progression.* -
- Conducted over one year, the trial compared the effects of evolocumab plus guideline-directed medical therapy (GDMT) against GDMT alone, finding no significant change in troponin levels but noted decreases in NT-proBNP and ST2 levels in the intervention group.* -
- Results indicated a significant reduction in total and LDL cholesterol in the evolocumab group, while PCSK9 levels also increased, although the overall findings were limited and do not establish clear
Article Synopsis
- Meteorin-like protein (Metrnl) is a cytokine that plays a role in reducing inflammation and its high levels are linked to poorer outcomes in heart failure patients.
- This study focused on patients with ST-segment elevation myocardial infarction (STEMI) and measured Metrnl levels to evaluate its predictive power for health outcomes over three years.
- Results showed that higher Metrnl levels correlated with greater risks of death or nonfatal heart attacks, indicating it could be a significant prognostic biomarker for complications in STEMI patients.
Article Synopsis
- Myocardial fibrosis can worsen prognosis in heart failure patients, even if they show left ventricular reverse remodeling (LVRR) after treatment.
- This study analyzed the levels of specific collagen-derived peptides in 1,034 heart failure patients to evaluate their association with heart function recovery and overall outcomes.
- Results showed that patients with low levels of procollagen type I C-terminal propeptide (PICP) had better heart function improvements and lower risks of heart failure-related issues, especially in women and nonischemic cases.
- The findings suggest that measuring PICP levels could help identify patients who are more likely to respond positively to treatment and enhance their clinical outcomes.